|
Remicade
|
|
Infliximab What is it? Infliximab is a Disease Modifying Anti Rheumatic Drug (DMARD), one of the new class called biologic response modifiers. FDA approved: November 1999 (for RA) How does it work? Tumor necrosis factor (TNF) alpha is a cytokine that plays a significant role in the inflammatory process in rheumatoid arthritis. Infliximab is an antibody that blocks the effects of TNF- alpha, thus reducing inflammation. Preliminary studies have demonstrated that infliximab can actually retard the destruction of joints by rheumatoid arthritis. Dosage: Infliximab is administered via IV. The recommended dose for the treatment of rheumatoid arthritis is 3 mg/kg per dose. The initial dose should be followed by doses two and six weeks after the first dose. The maintenance dose is given every eight weeks. How should I take it? It will be given in the doctor's office or out patient clinic. Contraindications: Infliximab should not be used in patients with serious infections. Drugs Interactions: Since this drug is new the interaction with other drugs has not been studied. There are no studies in pregnancy and/or nursing mothers. Use only if the benefit outweighs the unknown risk. Possible side effects: These side effects are
not considered serious but are certainly annoying for those experiencing them.
The most frequently reported side effects include headache, nausea and vomiting,
stomach upset, and tiredness. The drug is relatively new, so long term side effects may not yet be known. Precautions & Special Notes: Infliximab has been noted to increase the chance of serious infection. Report any and all signs of infection right away. For more information: |
|
DISCLAIMER: The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website. Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use. The International Still's Disease Foundation is a non-profit organization. This page was last updated on January 17, 2001 Copyright© 1999-2001 International Still's Disease Foundation |